Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Trevor M. Feinstein

Hematology Oncology | Hematology | Oncology
Piedmont Cancer Institute PC
1267 Hwy 54 W, Suite 4200, 
Fayetteville, GA 
Accepting New Patients
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Piedmont Cancer Institute PC
1267 Hwy 54 W, Suite 4200, 
Fayetteville, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Trevor Feinstein is a Hematologist Oncology specialist and a Hematologist in Fayetteville, Georgia. Dr. Feinstein is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Lung Cancer, Paget Disease of the Breast, and Familial Colorectal Cancer. Dr. Feinstein is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in GA
Hospital Affiliations
Piedmont Newnan Hospital, Inc
Piedmont Hospital, Inc
Piedmont Henry Hospital
Piedmont Fayette Hospital
Languages Spoken
English
Hebrew
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

PIEDMONT CANCER INSTITUTE PC
1267 Hwy 54 W, Suite 4200, Fayetteville, GA 30214
Call: 678-829-1060

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Docetaxel+Plinabulin, Docetaxel
Study Phase: Phase 3
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

5 Total Publications

Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 31, 2025
View All 5 Publications
Similar Doctors
Vasileios J. Assikis
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vasileios J. Assikis
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vasileios J. Assikis
Oncology | Hematology

Piedmont Cancer Institute, PC

1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 
 (8.7 miles away)
678-829-1060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vasileios Assikis is a Hematologist and an Oncologist in Fayetteville, Georgia. Dr. Assikis is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Assikis is currently accepting new patients.

Stephen M. Szabo
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stephen M. Szabo
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stephen M. Szabo
Hematology | Oncology

Piedmont Oncology At Rockdale

1412 Milstead Ave NE, Ste 300, 
Conyers, GA 
 (39.1 miles away)
770-918-2320
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Szabo is board certified in hematology, medical oncology, and internal medicine. He completed his hematology-oncology training at Emory University Hospital and his internal medicine residency at the University of Michigan Hospitals. He earned his medical degree at Cornell University Medical College.Dr. Szabo has been practicing medicine for more than 20 years. Most recently, he was Chief of Staff at Emory St. Joseph Hospital. Prior to that, he was Chief of Staff at Emory Johns Creek Hospital and the Director of the Division of Community Oncology for the Department of Hematology Oncology at Emory Healthcare.Dr. Szabo has special interests in breast cancer, gastrointestinal cancer, and benign and malignant hematology. In his free time, Dr. Szabo enjoys promoting health education, hiking, sailing, and spending time with his family.Dr. Szabo and the team at Piedmont Oncology have the resources you need conveniently close to home.Dr. Szabo is accepting new patients and welcomes most major insurance plans. Dr. Szabo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Hereditary Neuroblastoma, Inflammatory Breast Cancer, Gastric Lymphoma, Bone Marrow Aspiration, and Colonoscopy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Minesh D. Patel
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Minesh D. Patel
Hematology Oncology | Hematology | Oncology

Piedmont Cancer Institute PC

775 Poplar Rd, Suite 310, 
Newnan, GA 
 (9.9 miles away)
770-251-2590
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients
Offers Telehealth

Minesh Patel is a Hematologist Oncology specialist and a Hematologist in Newnan, Georgia. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Malabsorption, Vitamin B12 Deficiency, and Pleuropulmonary Blastoma. Dr. Patel is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feinstein's expertise for a condition
ConditionClose
    • Distinguished
    • Agranulocytosis
      Dr. Feinstein is
      Distinguished
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • Appendix Cancer
      Dr. Feinstein is
      Distinguished
      . Learn about Appendix Cancer.
      See more Appendix Cancer experts
    • Breast Cancer
      Dr. Feinstein is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Feinstein is
      Distinguished
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Colorectal Cancer
      Dr. Feinstein is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Dehydration
      Dr. Feinstein is
      Distinguished
      . Learn about Dehydration.
      See more Dehydration experts
    View All 17 Distinguished Conditions
    • Advanced
    • Acute Mountain Sickness
      Dr. Feinstein is
      Advanced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Adult Immune Thrombocytopenia
      Dr. Feinstein is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Feinstein is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Feinstein is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Alpha Thalassemia
      Dr. Feinstein is
      Advanced
      . Learn about Alpha Thalassemia.
      See more Alpha Thalassemia experts
    • Alpha Thalassemia X-Linked Intellectual Disability Syndrome
      Dr. Feinstein is
      Advanced
      . Learn about Alpha Thalassemia X-Linked Intellectual Disability Syndrome.
      See more Alpha Thalassemia X-Linked Intellectual Disability Syndrome experts
    View All 77 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Feinstein is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acquired Agranulocytosis
      Dr. Feinstein is
      Experienced
      . Learn about Acquired Agranulocytosis.
      See more Acquired Agranulocytosis experts
    • Acute Arterial Occlusion of Kidney
      Dr. Feinstein is
      Experienced
      . Learn about Acute Arterial Occlusion of Kidney.
      See more Acute Arterial Occlusion of Kidney experts
    • Acute Eosinophilic Pneumonia
      Dr. Feinstein is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Feinstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Feinstein is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    View All 188 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved